February 27, 2020 — Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center. The next-generation CyberKnife System has been shown to deliver precise stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) treatments with ease, making it possible for the clinical team to expand access to one of the most advanced methods for administering radiation to more cancer patients.
SRS and SBRT are non-invasive forms of radiation therapy that use high doses of very targeted radiation to destroy tumors, in just a few treatment sessions (1 to 5). SRS is commonly used to treat conditions within the brain and spine, while SBRT is used for those tumors located outside these areas. The CyberKnife M6 System is equipped with sophisticated functionality that will streamline the creation of personalized treatment plans and reduce the time to deliver radiation treatments, enabling the Mercy St. Louis team to offer precision SRS and SBRT treatments to more patients each day.
The Mercy Hospital St. Louis team uses the most advanced radiotherapy technology to design and deliver an individualized treatment plan designed to help cancer patients take control of their disease and resume their lives. The hospital is part of the Mercy system, named one of the top five large U.S. health systems from 2016 to 2019 by IBM Watson Health. Mercy announced in 2018 that it intended to work with Accuray to enhance cancer care through advanced life-saving technology, including the CyberKnife System that was recently installed as well as Accuray Radixact Systems that will be installed at other Mercy hospitals.
"The CyberKnife M6 is really an ideal system for the hospital and for our patients. The system combines sub-millimeter accuracy with real-time image guidance, enabling our team to effectively treat almost any part of the body requiring radiation therapy," said Robert Frazier, M.D., radiation oncologist and division chief for radiation oncology at Mercy Hospital St. Louis. "For example, when we treat patients with brain tumors, we will now be able to deliver a very high dose of radiation to the tumor, to eradicate the disease, while minimizing the dose to critical brain structures. Prostate cancer patients who would have been treated with daily radiation equal to 40-45 fractions over 8-9 weeks, can now be treated in just 5 fractions with the CyberKnife System. And, because CyberKnife prostate SBRT typically is associated with few side effects, these patients can return to their normal activity on the same day."
"We congratulate the Mercy Hospital St. Louis team on the installation of their CyberKnife M6 System. We are committed to supporting them in their goal to expand access to advanced radiotherapy. This most recent installation of the CyberKnife M6 System further demonstrates clinicians' confidence in the value the system will bring to their patients, their team and their hospital," said Joshua H. Levine, president and CEO at Accuray.
Important Safety Information
For Important Safety Information please refer to https://www.accuray.com/safety-statement.